Edesa Biotech, Inc. (EDSA) financial statements (2020 and earlier)

Company profile

Business Address 100 SPY COURT
MARKHAM, ON L3R 5H6
State of Incorp. BC
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
9/30/2018
9/30/2017
9/30/2016
9/30/2015
8/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments410711914
Cash and cash equivalents4457413
Short-term investments062450
Receivables000000
Inventory, net of allowances, customer advances and progress billings 0001 
Inventory 0001 
Prepaid expense000000
Deferred costs0     
Total current assets:5117121014
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment011110
Long-term investments and receivables 000  
Long-term investments 000  
Deposits noncurrent assets 00000
Total noncurrent assets:011110
TOTAL ASSETS:5128131014
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:100111
Other undisclosed accounts payable and accrued liabilities100111
Debt0     
Deferred revenue and credits  00
Other undisclosed current liabilities    21
Total current liabilities:100121
Noncurrent Liabilities
Long-term debt and lease obligation0     
Operating lease, liability0
Other undisclosed noncurrent liabilities     5
Total noncurrent liabilities:0    5
Total liabilities:100127
Stockholders' equity
Stockholders' equity attributable to parent, including:41171288
Common stock125748473836
Common stock, value, subscriptions0     
Additional paid in capital0     
Accumulated other comprehensive loss(0)     
Accumulated deficit(8)(50)(45)(40)(35)(34)
Other undisclosed stockholders' equity attributable to parent 54555
Total stockholders' equity:41171288
TOTAL LIABILITIES AND EQUITY:5128131014

Income statement (P&L) ($ in millions)

12/31/2019
TTM
9/30/2018
9/30/2017
9/30/2016
9/30/2015
8/31/2014
Revenues000110
Revenue, net0110
Cost of revenue(0)(0)(0)(0)(1)(1)
Cost of goods and services sold(0)   (1)(1)
Other cost of operating revenue (0)(0)(0)(0) 
Gross profit:0(0)(0)1(0)(1)
Operating expenses(6)(5)(5)(6)(5)(6)
Other undisclosed operating income0000  
Operating loss:(6)(5)(5)(5)(5)(7)
Nonoperating income (expense)000(0)2(3)
Investment income, nonoperating000000
Foreign currency transaction gain (loss), before tax(0)(0)00(1)(0)
Other undisclosed income from continuing operations before equity method investments, income taxes    11
Loss from continuing operations before income taxes:(5)(5)(5)(5)(3)(8)
Income tax expense(0)(0)(0)(0)(0)(0)
Loss before gain (loss) on sale of properties:(5)(5)(5)(5)(3)(8)
Other undisclosed net income0     
Net loss:(5)(5)(5)(5)(3)(8)
Other undisclosed net loss attributable to parent(0)     
Net loss available to common stockholders, diluted:(5)(5)(5)(5)(3)(8)

Comprehensive Income ($ in millions)

12/31/2019
TTM
9/30/2018
9/30/2017
9/30/2016
9/30/2015
8/31/2014
Net loss:(5)(5)(5)(5)(3)(8)
Comprehensive loss:(5)(5)(5)(5)(3)(8)
Other undisclosed comprehensive income, net of tax, attributable to parent0     
Comprehensive loss, net of tax, attributable to parent:(5)(5)(5)(5)(3)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: